Open AccessOral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
Author(s) -
Maria Rosaria Valerio,
P. Spadaro,
Concetta Arcanà,
Nicolò Borsellino,
Calogero Cipolla,
Paolo Vigneri,
Dario Piazza,
Vittorio Gebbia
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2020-0095
Subject(s) - vinorelbine , capecitabine , medicine , metastatic breast cancer , oncology , retrospective cohort study , breast cancer , chemotherapy , cancer , breast carcinoma , gastroenterology , surgery , colorectal cancer , cisplatin
A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m 2 on day 1 and 8, plus capecitabine 1000 mg/m 2 bid for 14 consecutive days every 3 weeks. Overall response rate was 53% with a 9% complete response rate. Stable disease was recorded in 27% of the cases. Median progression-free survival was 7.9 months and median overall survival was 29.2 months. Toxicity was generally mild and easily manageable. These data demonstrate that this combination is feasible, safe and active as first-line treatment of triple-negative fully hormone-resistant advanced breast carcinoma patients.